Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
The closing price of BioAtla Inc (NASDAQ: BCAB) was $0.58 for the day, down -7.32% from the previous closing price of $0.63. In other words, the price has decreased by -$7.32 from its previous closing price. On the day, 0.69 million shares were traded. BCAB stock price reached its highest trading level at $0.6419 during the session, while it also had its lowest trading level at $0.5647.
Ratios:
Our analysis of BCAB’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.24 and its Current Ratio is at 1.24.
On September 15, 2022, JMP Securities started tracking the stock assigning a Mkt Outperform rating and target price of $17.JMP Securities initiated its Mkt Outperform rating on September 15, 2022, with a $17 target price.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BCAB now has a Market Capitalization of 34040904 and an Enterprise Value of 21878904. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.09. Its current Enterprise Value per Revenue stands at 1.989 whereas that against EBITDA is -0.35.
Stock Price History:
The Beta on a monthly basis for BCAB is 1.00, which has changed by -0.6408669 over the last 52 weeks, in comparison to a change of 0.16333759 over the same period for the S&P500. Over the past 52 weeks, BCAB has reached a high of $2.53, while it has fallen to a 52-week low of $0.24. The 50-Day Moving Average of the stock is 27.31%, while the 200-Day Moving Average is calculated to be 17.19%.
Shares Statistics:
BCAB traded an average of 781.44K shares per day over the past three months and 1064920 shares per day over the past ten days. A total of 58.72M shares are outstanding, with a floating share count of 44.67M. Insiders hold about 23.93% of the company’s shares, while institutions hold 15.47% stake in the company. Shares short for BCAB as of 1756425600 were 3978046 with a Short Ratio of 5.09, compared to 1753920000 on 3919687. Therefore, it implies a Short% of Shares Outstanding of 3978046 and a Short% of Float of 7.6.
Earnings Estimates
The current rating of BioAtla Inc (BCAB) reflects the combined expertise of 3.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.3, with high estimates of -$0.22 and low estimates of -$0.36.
Analysts are recommending an EPS of between -$1.06 and -$1.3 for the fiscal current year, implying an average EPS of -$1.19. EPS for the following year is -$1.2, with 3.0 analysts recommending between -$0.71 and -$1.59.
